Metabolic adaptations to interrupted glycosaminoglycan recycling.
Lysosomal storage diseases (LSD) are metabolic disorders characterized by accumulation of undegraded material. The mucopolysaccharidoses (MPS) are LSDs defined by the storage of glycosaminoglycans. Previously, we hypothesized that cells affected with LSD have increased energy expenditure for biosynthesis because of deficiencies of raw materials sequestered within the lysosome. Thus, LSDs can be characterized as diseases of deficiency as well as overabundance (lysosomal storage). In this study, metabolite analysis identified deficiencies in simple sugars, nucleotides, and lipids in the livers of MPSI mice. In contrast, most amino acids, amino acid derivatives, dipeptides, and urea were elevated. These data suggest that protein catabolism, perhaps because of increased autophagy, is at least partially fulfilling intermediary metabolism. Thus, maintaining glycosaminoglycan synthesis in the absence of recycled precursors results in major shifts in the energy utilization of the cells. A high fat diet increased simple sugars and some fats and lowered the apparent protein catabolism. Interestingly, autophagy, which is increased in several LSDs, is responsive to dietary intervention and is reduced in MPSVII and MPSI mice fed a high fat diet. Although long term dietary treatment improved body weight in MPSVII mice, it failed to improve life span or retinal function. In addition, the ventricular hypertrophy and proximal aorta dilation observed in MPSVII mice were unchanged by a high fat, simple sugar diet. As the mechanism of this energy imbalance is better understood, a more targeted nutrient approach may yet prove beneficial as an adjunct therapy to traditional approaches.
Woloszynek
Josh C
JC
Department of Internal Medicine, Washington University School of Medicine, St. Louis, Missouri 63110, USA.
Kovacs
Atilla
A
Ohlemiller
Kevin K
KK
Roberts
Marie
M
Sands
Mark S
MS
D000818:Animals; D001343:Autophagy / Q000187:drug effects; D004040:Dietary Carbohydrates / Q000494:pharmacology; D004041:Dietary Fats / Q000494:pharmacology; D004734:Energy Metabolism; D006025:Glycosaminoglycans / Q000378:metabolism*; D008136:Longevity / Q000187:drug effects; D008247:Lysosomes / Q000378:metabolism*; D051379:Mice; D009083:Mucopolysaccharidoses / Q000178:diet therapy / Q000378:metabolism* / Q000473:pathology
D004040:Dietary Carbohydrates; D004041:Dietary Fats; D006025:Glycosaminoglycans; C020341:glucosaminoglycans
Proc Natl Acad Sci U S A. 2004 Jan 13;101(2):603-8
14704281
Am J Hum Genet. 2007 Nov;81(5):1070-83
17924347
Science. 1968 Nov 1;162(3853):570-2
4236721
PLoS One. 2007 Aug 22;2(8):e772
17712420
FEBS Lett. 1993 Jul 12;326(1-3):267-71
8325377
J Inherit Metab Dis. 2009 Apr;32(2):181-9
19130290
Br J Haematol. 2005 Feb;128(4):413-31
15686451
PLoS Genet. 2005 Jul;1(1):81-95
16103921
Ann Neurol. 2006 Apr;59(4):700-8
16532490
J Cell Physiol. 2009 May;219(2):344-53
19117012
Biochem Biophys Res Commun. 2008 Mar 14;367(3):616-22
18190792
Hum Mol Genet. 2008 Jan 1;17(1):119-29
17913701
Physiol Rev. 1992 Oct;72(4):881-940
1438581
Dev Biol. 2006 May 15;293(2):382-91
16530747
Biochem J. 2004 Apr 15;379(Pt 2):461-9
14705966
Am J Pathol. 2005 Dec;167(6):1713-28
16314482
J Inherit Metab Dis. 2006 Apr-Jun;29(2-3):332-40
16763896
Pediatr Dev Pathol. 2008 May-Jun;11(3):185-92
17990914
J Biol Chem. 2007 Dec 7;282(49):35765-71
17911106
J Clin Invest. 2002 Jul;110(2):259-69
12122118
Diabetes Metab Res Rev. 1999 Jul-Aug;15(4):261-73
10495475
Exp Eye Res. 2000 Nov;71(5):469-81
11040082
Hum Mol Genet. 2008 Sep 1;17(17):2723-37
18550655
J Lipid Res. 2001 Apr;42(4):489-500
11290820
Biochem J. 1986 May 1;235(3):707-13
3753439
Hum Mol Genet. 2009 Mar 1;18(5):956-65
19074461
Expert Rev Cardiovasc Ther. 2007 Nov;5(6):1123-34
18035928
Cell. 2008 Nov 28;135(5):838-51
19041749